BASKING RIDGE, N.J., July 20 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the expansion of its Medical Advisory Board (MAB). Three new members (Dr. John Eikelboom of Canada, Dr. Philippe Menasche of France and Dr. Lars Wallentin of Sweden) join the original members bringing the current size of the MAB to twelve. Regado's MAB comprises leaders in the fields of cardiology, thrombosis/coagulation and cardiovascular surgery who advise the Company on its clinical programs and provide strategic guidance to support the eventual commercialization of Regado's products, in particular, the Company's leading product candidate, the REG1 anticoagulation system.
Robert A. Harrington, M.D., Chairman of Regado's Medical Advisory Board, stated, "The addition of Drs. Eikelboom, Menasche and Wallentin brings increased expertise and further diversification to the experience and perspective of an already prominent group of physicians. This expanded board will play an important role in the global development of Regado's overall aptamer/reversal agent antithrombotic technology platform, including the REG1 anticoagulant system as it enters phase 2b with the RADAR trial."
Steven L. Zelenkofske, D.O., F.A.C.C., Chief Medical Officer of Regado, said, "We are very pleased to welcome the new members to our Medical Advisory Board and look forward to the knowledge, guidance and creativity that they will contribute to our development programs." David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado, added, "The addition of these three new members reinforces the leadership position of Regado in the field of antithrombotic aptamers with specific, active control agents. Our Medical Advisory Board continues to be a key asset in the achievement of Regado's strategic imperatives."
|SOURCE Regado Biosciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved